Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Epkinly Market Forecast: What Market Value Is Expected By 2030?
The historic period’s growth was driven by a higher prevalence of non-Hodgkin lymphoma, the constraints of standard chemotherapy, progress in monoclonal antibody development, a greater number of approvals for targeted cancer therapies, and persistent gaps in treating relapsed cancers.
Several factors are expected to drive growth during the forecast period, including the rising uptake of immuno-oncology treatments, a broadening range of clinical uses for bispecific antibodies, stronger evidence of improved patient outcomes, higher expenditures on cancer care, and the proliferation of specialized cancer treatment facilities. Key developments anticipated in this timeframe encompass immunotherapies centered on bispecific antibodies, the growth of T-cell engaging drugs for oncology, a targeted emphasis on lymphoma cases that are relapsed or refractory, the adoption of subcutaneous methods for delivering cancer medications, and the advancement of tailored therapeutic approaches for hematologic malignancies.
Download A Free Sample Report For Comprehensive Market Insights:
Epkinly Market Growth Drivers And Industry Catalysts
The future expansion of the epkinly market is expected to be fueled by the increasing demand for targeted therapies. These therapies are designed as precise interventions that inhibit specific molecules responsible for disease progression, particularly in cancers, while offering fewer adverse effects compared to conventional treatments. Their growing popularity stems from the ability to deliver more effective, personalized care with reduced toxicity. Epkinly (epcoritamab) functions within targeted therapy for relapsed or refractory B-cell non-Hodgkin lymphoma by attaching to CD3 on T cells and CD20 on B cells, thereby guiding the immune system to eliminate malignant B cells. As an illustration, in October 2024, the National Health Service, a UK government entity, reported that during 2023/24, 14.5% of hormone replacement therapy (HRT) items were linked to an HRT prescription prepayment certificate (PPC). By June 2024, this figure had climbed to 21%, up from 9.7% in June 2023. Consequently, the heightened need for targeted therapies is propelling growth in the epkinly market.
Epkinly Market Categorization By Product Type And Application
The epkinly market covered in this report is segmented –
1) By Indication: Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), Indolent Lymphoma
2) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies
Epkinly Market Trends Influencing Long-Term Demand
Key developments in the epkinly market are centered on securing regulatory approvals for novel therapies, particularly bispecific antibody treatments, aimed at improving treatment effectiveness and broadening available options. Bispecific antibody therapies represent a form of immunotherapy where antibodies are engineered to simultaneously bind to two distinct antigens or targets. As an example, in June 2024, AbbVie Inc., a biotechnology firm based in the United States, obtained FDA approval for EPKINLY (epcoritamab-bysp), marking it as the first bispecific antibody indicated for adults with relapsed or refractory follicular lymphoma (FL) following at least two prior lines of systemic therapy. This innovative approach activates the immune system by targeting both CD20 and CD3, achieving a notable overall response rate of 82% during clinical trials. Delivered subcutaneously through a step-up dosing schedule, EPKINLY provides a fresh alternative for patients who have exhausted other options. This regulatory milestone represents a substantial step forward in managing follicular lymphoma, offering renewed optimism for enhanced patient outcomes.
Epkinly Market Company Landscape And Strategic Competition
Major companies operating in the epkinly market are AbbVie Inc., Genmab A/S.
Access The Complete Epkinly Market Report:
Epkinly Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the epkinly market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the epkinly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model